Early-stage tests of the drug BMS-936558, known as an anti-PD-1 treatment, showed it was relatively safe and shrank tumors in three of the five cancer types studied, the team reported at the American Society of Clinical Oncology (ASCO) meeting on Saturday and published online in the New England Journal of Medicine.
The team saw significant tumor shrinkage in 18 percent of the 76 lung cancer patients, 28 percent of the 94 melanoma patients, and 27 percent of the 33 patients with kidney cancer.
"These are significant regression rates, especially considering the kind of patient we are treating," said Dr. Suzanne Topalian, professor of surgery and oncology at Johns Hopkins Kimmel Cancer Center, who presented the findings at the ASCO cancer meeting, noting that many of the patients in the study had been treated with at least three other drugs.
A high-powered ultrasound beam can destroy prostate cancer without causing the serious side effects that plague other treatments, a London study found.
Trials in London and Basingstoke, southeastern England, found it was possible to obliterate tumor cells without damaging delicate surrounding tissues.
Conventional surgery or radiotherapy for prostate cancer leaves half of men impotent and a fifth incontinent. The side effects are so common that many men with slow-growing tumors are advised not to have treatment.
Doctors used an experimental procedure High Intensity Focused Ultrasound (HIFU) to destroy tumors during the trial.
None of the 41 men treated had incontinence and only 10 percent had impotence, the Lancet Oncology journal reported.
The virus, known as adeno-associated virus type 2 (AAV2), is naturally occurring and carried by up to 80 percent of humans, but it does not cause any disease.
Researchers learned of its cancer-killing properties in 2005, after Penn State scientists observed it killing cervical cancer cells. They also found that women who carried the AAV2 virus and human papillomavirus (HPV), which causes cervical cancer, had a lower propensity to develop cervical cancer.
When combined in a lab recently, AAV2 eradicated all the breast cancer cells "within seven days," according to researchers. Better still, it proved capable of wiping out cancer cells at multiple stages, negating the need for differing treatments used today.
The giant keyhole limpet's hemolymph carries a protein that is the essential component of a new cancer vaccine. Keyhole limpet hemocyanin (KLH) carries oxygen in limpet blood. It is an unusually large protein - near virus size - and contains many epitopes, which trigger our body to produce antibodies. When doctors inject KLH into the human bloodstream, it provokes a powerful immune response. If markers for a certain cancer are attached to KLH, the immune system can be stimulated to attack them. Unlike some synthetic alternatives, KLH is nontoxic. Researchers use the protein in cancer vaccines to "break tolerance," says Frank Oakes, the CEO of Stellar Biotechnologies, which grows limpets in a business park for aquaculture next to the Pacific Ocean in Port Hueneme, California. "Your body tolerates the cancer cell because the body believes it is a part of you," he says.
More than a dozen vaccines that use KLH are in clinical trials, and a treatment for bladder cancer is now approved for use in Europe and Asia. Stellar currently has the capacity to make between one and two kilograms of KLH a year. But if a KLH cancer vaccine is FDA-approved, Oakes says it "will increase demand by orders of magnitude."
Cancer cells usually evade patient's immune systems because they are not recognised as being a threat. While the immune system usually attacks foreign cells such as bacteria, tumours are formed of the patient's own cells that have malfunctioned.
Scientists have, however, found that a molecule called MUC1, which is found in high amounts on the surface of cancer cells, can be used to help the immune system detect tumours.
The new vaccine, developed by drug company Vaxil Biotheraputics along with researchers at Tel Aviv University, uses a small section of the molecule to prime the immune system so that it can identify and destroy cancer cells.
A statement from Vaxil Biotheraputics said: "ImMucin generated a robust and specific immune response in all patients which was observed after only 2-4 doses of the vaccine out of a maximum of 12 doses.
Topical application of saffron extract (100 mg/kg body wt) inhibited two-stage initiation/promotion dimethylbenz[a]anthracene (DMBA)-induced skin carcinogenesis and oral administration of saffron extract in the same dose restricted 20-methylchloanthrene (MCA)-induced soft tissue sarcomas in mice.
Later, it was demonstrated that saffron extract significantly prolonged (almost 3-fold) the life spans of cisplatin-treated (2 mg/kg body wt) mice and partially prevented the decrease in body weight, hemoglobin levels, and leukocyte counts.
Oral administration of saffron extract (200 mg/kg body wt) induced a dose-dependent inhibition of the growth in mice of ascite tumors derived from sarcoma-180 (S-180), Ehrlich ascites carcinoma (EAC), Dalton's lymphoma ascites (DLA), and significantly increased (2- to 3-fold) life spans of treated tumor-bearing mice.
One of the misconceptions that people have about a cell is that it contains a nucleus, a cell wall and everything inside (cytoplasm) kind of sloshes around in a liquid or gel. In fact, the inside of a cell contains a kind of scaffold made of micro-tubules, also called spindles, that have the ability to assemble and disassemble quicky. This network of rigid micro-tubules inside the cell gives it shape, structure and also has the ability to transfer organelles and various molecules to different parts within the cell, functioning like a railway system. But its most vital function is cell division.
Mebendazole is known to interfere and inhibit the assembly of the spindles, thus preventing the ability of the cells to divide. The cell eventually dies of old age or aptosis. Mebendazole is highly selective and somehow targets only cancerous cells (as well as a host of intestinal parasites). At the end of this article I will post a few of the many scientific papers acknowledging these facts.
The action of mebendazole on cancer cells does not have much to do with it being a worm killer. Other meds and herbs that kill worms would be unlikely to work for cancer. Mebendazole damages tubulin in cancer cells. It interrupts the cell cycle before the cells go into mitosis. It also stimulates apoptosis, natural cell death. It also seems to block angeogenesis, meaning it stops blood vessel growth to tumors.
Contortrostatin (CN) is a member of a family of peptides called disintegrins that are found in snake venoms. Members of this family are distinguished by the presence of an amino acid sequence, arginine-glycine-aspartic acid (RGD), that enables them to bind to cell surface receptors called integrins found on cancer cells and newly growing (angiogenic) blood vessels in the tumor. Integrins mediate interactions between cells and their surroundings, and on cancer cells they play important roles in tumor invasion and dissemination.
Information has been published in medical journals for almost a decade, about the cancer-fighting properties of the Southern Copperheads venom. A protein in the venom called contortrostatin (CN) causes a disruption in the tumor cell's ability to adhere to and invade neighbor cells while also inhibiting the development of new blood vessels required to sustain the tumor.
CN belongs to a class of proteins known as disintegrins, called that because they disrupt the function of certain other proteins, called integrins, on the surface of cells. Integrins are involved in the adhesive phenomenon of cells. CN is effective in retarding the spread of tumor cells because it inhibits their adhesion to and invasion of normal cells in the surrounding tissue.
More than half of all human cancers have lost the p53 gene. Yet even in an era of molecularly targeted therapies scientists have had trouble figuring out how to compensate for the absence of a gene. Unlike a genetic mutation that changes the function or activity of a gene, which can be inhibited by a well-tailored drug, loss of a gene leaves nothing for the drug to target.
Thompson and his team, however, have been accumulating evidence over the last several years that p53, best known as a regulator of cell division, controls several metabolic pathways in cells. For potential cancer therapies, that means a drug that affects pathways controlled by p53 could help control p53-deficient tumors.
Significantly, the regulation of metabolic pathways by p53 is also influenced by metformin, the most widely used diabetes drug. Metformin activates the metabolic enzyme AMPK (AMP activated protein kinase), which exerts changes on cellular metabolism by affecting p53 function. Two observational studies already show that diabetic patients who take metformin have a lower rate of cancer diagnosis and mortality than other diabetics.
This discovery by Kaali and Lyman in the Fall of 1990 at the Albert Einstein College of Medicine, N.Y.C. in 1990 was the centerpiece of Dr. Bob Beck's lectures on blood electrification. Kaali and Lyman re-discovered something that Dr. Robert O. Becker had also came upon in the 1970's and 80's in that direct current applied at very low voltage, delivered in the 50-100 microampere range effected amazing cellular response and achieved the de-activation of pathogenic organisms.
Preferred electrifiers must generate a 3.9 Hz (not critical) biphasic sharp-rise-time square wave, +/- 27 volt peak adjustable output, 50% duty cycle, capable of delivering several milliamperes into a low resistance load at skin surface (+/- 2000 ohm impedance) which after losses in tissue resistance delivers the necessary 50 to 100 microamperes through flowing blood.
This suppressed medical discovery is proving to neutralize or eliminate all parasites and their mycotoxins, fungi, viruses, microbes, germs, pathogens, bacteria, or any other foreign invaders in blood without drugs.
There are no known side effects to healthy cells, tissue, or fluids. Elimination of blood pathogens can be verified by examining blood under dark field/phase contrast microscopy.
I didn't see it listed here, maybe on your other thread, but have you heard of IP6?